Title

787901 - Gender Differences and Survival Outcomes in Breast Cancer Patients: Stage stratified Propensity Scoring Analysis of NCDB

Document Type

Article

Publication Date

5-2020

Publication Title

Annals of Surgical Oncology

Abstract

Background/Objective: There is limited research examining breast cancer gender differences. This study compares the trends and survival outcomes over the years between male (MBC) and female (FBC) breast cancer patients using the National Cancer Database (NCDB). Methods: We retrospectively analyzed the NCDB registry for MBC and FBC cases diagnosed between 2004 and 2014. Patient demographics, tumor characteristics, overall mortality (OM), and trends were compared between MBC and FBC Patients. Univariate, multivariate, and propensity score weighted analyses were done to compare MBC and FBC. Results: A total of 19,488 MBC patients (0.9%) and 2,138,730 FBC patients (99.1%) were identified. Median follow-up was 59.63 months. Compared with FBC group, MBC group was more likely to be older (Mean:64, SD:13 vs. Mean:60, SD 13.3), African American or nonHispanic, have more comorbidities, and have a hormonally positive tumor with a higher stage at diagnosis (all p<0.001). From 2004 to 2014, Stage II (1.21% to 1.34%-p=0.001) and IV (0.88% to 1.43%-p=0.046) diagnoses significantly increased more for MBC than FBC (p<0.05). Surgery, radiation, and chemotherapy were used less in MBC regardless of stage (all p<0.001). However, hormonal therapy was used more in MBC for Stages III and IV ( P<0.001). There was no significant change in 5-year overall survival from 2004 to 2010 for MBC (77.21% to 74.1%, p=0.13), while FBC 5-year overall survival significantly increased (83.84% to 85.31%, p<0.001). In the adjusted stage-stratified propensity score weighted analysis, there was a 21% lower hazard of OM in Stage 0 (HR:0.79; p=0.048) and a 21% higher hazard of OM in Stage II (HR:1.21; p<0.001) MBC cases compared to FBC cases. There was no statistical difference between MBC and FBC in OM for Stage I (HR:1.04; p=0.52), III (HR:1.01; p=0.88) or IV (HR:1.03; p=0.59) cases. Conclusions: Our data suggest that there are some significant differences in the trends and survival outcomes of MBC in comparison to FBC. This data may help identify the areas that need further research and care optimization for MBC.

Volume

27

Issue

2

First Page

397

Last Page

398

This document is currently not available here.

Share

COinS